Compare UBCP & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBCP | ELTX |
|---|---|---|
| Founded | 1902 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.6M | 81.2M |
| IPO Year | 1995 | 2014 |
| Metric | UBCP | ELTX |
|---|---|---|
| Price | $15.46 | $2.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 1.6K | ★ 255.7K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.73% | N/A |
| EPS Growth | 5.51 | ★ 39.29 |
| EPS | ★ 0.69 | N/A |
| Revenue | N/A | ★ $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.58 | N/A |
| P/E Ratio | $22.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.47 | $2.66 |
| 52 Week High | $17.34 | $16.00 |
| Indicator | UBCP | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.19 | 33.30 |
| Support Level | $14.97 | N/A |
| Resistance Level | $16.10 | $3.32 |
| Average True Range (ATR) | 0.31 | 0.13 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 15.07 | 0.74 |
United Bancorp Inc operates as a bank holding company that provides commercial and retail banking services. Through its subsidiary (Unified Bank), the company provides a broad range of banking and financial services, which include accepting demand, savings, and time deposits and granting commercial, real estate, and consumer loans. The Company's primary deposit products are checking, savings, and term certificate accounts, and its primary lending products are residential mortgage, commercial, and installment loans. The bank also operates in Marshall County, West Virginia.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.